Spyre Therapeutics (SYRE) EBT (2015 - 2026)
Spyre Therapeutics (SYRE) reported EBT of -$69.0 million for Q1 2026, down 54.07% on a YoY basis from -$150.2 million in Q1 2025, and down 10.36% quarter-over-quarter from -$62.5 million in Q4 2025.
Spyre Therapeutics (SYRE) EBT (2015 - 2026) Analysis & Trends
Spyre Therapeutics has reported EBT for 12 years, with the latest figure at -$69.0 million in Q1 2026.
- For the quarter ending Q1 2026, EBT fell 54.07% year-over-year to -$69.0 million; the trailing twelve-month figure through Mar 2026 stood at -$179.4 million (up 14.12% YoY), and the FY2025 full-year result was -$155.2 million, up 25.36% from the prior year.
- EBT for Q1 2026 stood at -$69.0 million, down from -$62.5 million in the prior quarter.
- The five-year high for EBT was -$11.2 million in Q3 2025, with the low at -$217.1 million in Q2 2023.
- Historically, EBT has averaged -$50.3 million across 5 years, with a median of -$40.1 million in 2023.
- Annual changes were most pronounced in 2023 — EBT plunged 872.82% — and 2025, when it soared 83.8%.
- Spyre Therapeutics' EBT stood at -$18.8 million in 2022, then sank by 236.35% to -$63.2 million in 2023, then rose by 10.9% to -$56.3 million in 2024, then decreased by 11.08% to -$62.5 million in 2025, then dropped by 10.36% to -$69.0 million in 2026.
- The last three EBT figures came in at -$69.0 million (Q1 2026), -$62.5 million (Q4 2025), and -$11.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 19.60 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.18 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -15.31 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.25 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Spyre Therapeutics | 6.95 Bn | 6.95 Bn | - | -69.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -69.01 Mn |
| Dec 31, 2025 | -62.53 Mn |
| Sep 30, 2025 | -11.18 Mn |
| Jun 30, 2025 | -36.72 Mn |
| Mar 31, 2025 | -44.79 Mn |
| Dec 31, 2024 | -56.30 Mn |
| Sep 30, 2024 | -69.01 Mn |
| Jun 30, 2024 | -38.84 Mn |
| Mar 31, 2024 | -43.83 Mn |
| Dec 31, 2023 | -63.18 Mn |
| Sep 30, 2023 | -40.10 Mn |
| Jun 30, 2023 | -217.07 Mn |
| Mar 31, 2023 | -18.46 Mn |
| Dec 31, 2022 | -18.78 Mn |
| Sep 30, 2022 | -18.44 Mn |
| Jun 30, 2022 | -22.31 Mn |
| Mar 31, 2022 | -24.44 Mn |
| Dec 31, 2021 | -20.42 Mn |
| Sep 30, 2021 | -20.28 Mn |
| Jun 30, 2021 | -6.74 Mn |